Astellas Pharma Inc. (ALPMY)
USD 9.14
(2.93%)
USD 9.14
(2.93%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 1034.29 Billion JPY | 41.84% |
| 2023 | 906.4 Billion JPY | 14.03% |
| 2022 | 794.85 Billion JPY | 9.06% |
| 2021 | 728.8 Billion JPY | 0.73% |
| 2020 | 723.52 Billion JPY | 3.52% |
| 2019 | 698.94 Billion JPY | -0.01% |
| 2018 | 698.98 Billion JPY | 2.96% |
| 2017 | 678.9 Billion JPY | -6.25% |
| 2016 | 724.14 Billion JPY | -0.3% |
| 2015 | 726.31 Billion JPY | 5.43% |
| 2014 | 688.89 Billion JPY | 23.32% |
| 2013 | 558.61 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 271 Billion JPY | -1.05% |
| 2024 Q1 | 232.77 Billion JPY | 1.48% |
| 2024 FY | 1034.29 Billion JPY | 14.11% |
| 2024 Q2 | 256.63 Billion JPY | 10.25% |
| 2024 Q3 | 273.88 Billion JPY | 6.72% |
| 2023 FY | 906.4 Billion JPY | 14.03% |
| 2023 Q4 | 229.37 Billion JPY | -0.23% |
| 2023 Q3 | 229.89 Billion JPY | 4.63% |
| 2023 Q2 | 219.73 Billion JPY | -3.37% |
| 2023 Q1 | 227.4 Billion JPY | 7.89% |
| 2022 Q4 | 210.78 Billion JPY | 8.37% |
| 2022 FY | 794.85 Billion JPY | 9.06% |
| 2022 Q3 | 194.5 Billion JPY | 0.18% |
| 2022 Q2 | 194.14 Billion JPY | -0.65% |
| 2022 Q1 | 195.42 Billion JPY | -0.77% |
| 2021 Q4 | 196.94 Billion JPY | 6.66% |
| 2021 Q2 | 222.55 Billion JPY | 19.33% |
| 2021 Q1 | 186.5 Billion JPY | -25.26% |
| 2021 FY | 728.8 Billion JPY | 0.73% |
| 2021 Q3 | 184.64 Billion JPY | -17.04% |
| 2020 Q3 | 179.83 Billion JPY | 10.42% |
| 2020 Q1 | 186.53 Billion JPY | -6.8% |
| 2020 FY | 723.52 Billion JPY | 3.52% |
| 2020 Q2 | 162.86 Billion JPY | -12.69% |
| 2020 Q4 | 249.53 Billion JPY | 38.76% |
| 2019 Q4 | 200.15 Billion JPY | 4.66% |
| 2019 Q2 | 181.91 Billion JPY | -6.62% |
| 2019 FY | 698.94 Billion JPY | -0.01% |
| 2019 Q1 | 194.8 Billion JPY | -6.82% |
| 2019 Q3 | 191.23 Billion JPY | 5.12% |
| 2018 Q4 | 209.06 Billion JPY | 12.46% |
| 2018 Q3 | 185.9 Billion JPY | -4.71% |
| 2018 Q2 | 195.09 Billion JPY | -2.34% |
| 2018 Q1 | 199.77 Billion JPY | 6.57% |
| 2018 FY | 698.98 Billion JPY | 2.96% |
| 2017 Q3 | 175.12 Billion JPY | 0.08% |
| 2017 Q4 | 187.45 Billion JPY | 7.04% |
| 2017 FY | 678.9 Billion JPY | -6.25% |
| 2017 Q1 | 173.42 Billion JPY | -12.33% |
| 2017 Q2 | 174.98 Billion JPY | 0.9% |
| 2016 Q1 | 191.66 Billion JPY | -1.56% |
| 2016 FY | 724.14 Billion JPY | -0.3% |
| 2016 Q4 | 197.81 Billion JPY | 2.44% |
| 2016 Q3 | 193.1 Billion JPY | -0.87% |
| 2016 Q2 | 194.8 Billion JPY | 1.63% |
| 2015 FY | 726.31 Billion JPY | 5.43% |
| 2015 Q2 | 163.56 Billion JPY | -2.99% |
| 2015 Q4 | 194.7 Billion JPY | -2.37% |
| 2015 Q3 | 199.43 Billion JPY | 21.93% |
| 2015 Q1 | 168.6 Billion JPY | -12.15% |
| 2014 Q2 | 159.57 Billion JPY | 0.16% |
| 2014 Q3 | 178.07 Billion JPY | 11.59% |
| 2014 FY | 688.89 Billion JPY | 23.32% |
| 2014 Q4 | 191.92 Billion JPY | 7.78% |
| 2014 Q1 | 159.31 Billion JPY | -6.38% |
| 2013 Q4 | 170.17 Billion JPY | 21.22% |
| 2013 Q3 | 140.38 Billion JPY | 12.14% |
| 2013 FY | 558.61 Billion JPY | 0.0% |
| 2013 Q2 | 125.19 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AstraZeneca PLC | 29.57 Billion USD | -3396.846% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | -5958.796% |
| CSPC Pharmaceutical Group Limited | 2.14 Billion USD | -48074.914% |
| Clarus Therapeutics Holdings, Inc. | 50.96 Million USD | -2029166.809% |
| Novartis AG | 24.87 Billion USD | -4058.647% |
| PT Kalbe Farma Tbk. | 11823.24 Billion USD | 91.252% |